Table 2 Correlations between body composition parameters and clinicopathological variable with tumor response to immune checkpoint inhibitors
Variables | Â | Tumor response | p value | |
|---|---|---|---|---|
PR | SD/PD | |||
Age | < 65 | 13 (24.1%) | 41 (75.9%) | 0.012 |
≥ 65 | 37 (45.7%) | 44 (54.3%) | ||
Sex | Female | 45 (42.9%) | 60 (57.1%) | 0.010 |
Male | 5 (16.7%) | 25 (83.3%) | ||
BMI | < 25 | 35 (33.0%) | 71 (67.0%) | 0.083 |
≥ 25 | 15 (51.7%) | 14 (48.3%) | ||
Smoking status | Never smoker | 9 (24.3%) | 28 (75.7%) | 0.075 |
Ever-smoker | 41 (41.8%) | 57 (58.2%) | ||
ECOG PS | 0–1 | 49 (38.0%) | 80 (62.0%) | 0.412 |
≥ 2 | 1 (16.7%) | 5 (83.3%) | ||
Histologic type | Squamous cell carcinoma | 11 (26.8%) | 30 (73.2%) | 0.123 |
Non-squamous cell carcinoma | 39 (41.5%) | 55 (58.5%) | ||
PD-L1 expression | Negative | 7 (25.0%) | 21 (75.0%) | 0.097 |
Positive | 31 (43.1%) | 41 (56.9%) | ||
Type of ICI | Anti-PD-1 or anti-PD-L1 monotherapy | 39 (37.1%) | 66 (63.3%) | 1.000 |
ICI-based combination therapy | 11 (36.7%) | 19 (63.3%) | ||
No. of lines of prior chemotherapy | 0 | 17 (56.7%) | 13 (43.3%) | 0.018 |
≥ 1 | 33 (31.4%) | 72 (68.6%) | ||
Skeletal muscle index | Q1 | 12 (37.5%) | 20 (62.5%) | 0.951 |
Q2–4 | 38 (36.9%) | 65 (63.1%) | ||
Total fat index | Q1 | 10 (29.4%) | 24 (70.6%) | 0.313 |
Q2–4 | 40 (39.6%) | 61 (60.4%) | ||
Visceral fat index | Q1 | 6 (18.2%) | 27 (81.8%) | 0.012 |
Q2–4 | 44 (43.1%) | 58 (56.9%) | ||
Subcutaneous fat index | Q1 | 12 (35.3%) | 22 (64.7%) | 0.898 |
Q2–4 | 38 (37.6%) | 63 (62.4%) | ||